한빛사논문
- 조회2,770
Abstract
Jungsu Kim1,2,3, Adam E.M. Eltorai1,2,3, Hong Jiang1,2,3, Fan Liao1,2,3, Philip B. Verghese1,2,3, Jaekwang Kim1,2,3, Floy R. Stewart1,2,3, Jacob M. Basak1,2,3, and David M. Holtzman1,2,3,*
1Department of Neurology, 2Hope Center for Neurological Disorders, and the, 3Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint Louis, MO 63110
*CORRESPONDENCE : David M. Holtzman
Abstract
The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for Alzheimer’s disease (AD). The influence of apoE on amyloid β (Aβ) accumulation may be the major mechanism by which apoE affects AD. ApoE interacts with Aβ and facilitates Aβ fibrillogenesis in vitro. In addition, apoE is one of the protein components in plaques. We hypothesized that certain anti-apoE antibodies, similar to certain anti-Aβ antibodies, may have antiamyloidogenic effects by binding to apoE in the plaques and activating microglia-mediated amyloid clearance. To test this hypothesis, we developed several monoclonal anti-apoE antibodies. Among them, we administered HJ6.3 antibody intraperitoneally to 4-mo-old male APPswe/PS1ΔE9 mice weekly for 14 wk. HJ6.3 dramatically decreased amyloid deposition by 60-80% and significantly reduced insoluble Aβ40 and Aβ42 levels. Short-term treatment with HJ6.3 resulted in strong changes in microglial responses around Aβ plaques. Collectively, these results suggest that anti-apoE immunization may represent a novel AD therapeutic strategy and that other proteins involved in Aβ binding and aggregation might also be a target for immunotherapy. Our data also have important broader implications for other amyloidosis. Immunotherapy to proteins tightly associated with misfolded proteins might open up a new treatment option for many protein misfolding diseases.
논문정보
- Research article
- 2012년 11월 (BRIC 등록일 )
- 국외 연구진
- 생명과학 > 신경생물학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
